US infant mortality dropped in 2024. Experts partly credit RSV shots
NEW YORK (AP) — The nation's infant mortality rate dropped last year after two years of hovering at a late-pandemic plateau.
Some experts think one reason for the drop could be a vaccination campaign against RSV, or respiratory syncytial virus, which is a common cause of cold-like symptoms that can be dangerous for infants.
The infant mortality national rate dropped to about 5.5 infant deaths per 1,000 live births in 2024, according to provisional data from the Centers for Disease Control and Prevention posted Thursday. That's down from about 5.6 per 1,000 live births, where it had been the previous two years.
CDC officials believe the findings will not change much when the final numbers come out later this year.
Infant mortality is the measure of how many babies die before they reach their first birthday. Because the number of babies born in the U.S. varies from year to year, researchers instead calculate rates to better compare infant mortality over time.
U.S. infant deaths fell to about 19,900 last year, according to CDC data, compared with about 20,150 in 2023.
The U.S. infant mortality rate has been worse than other high-income countries, which experts have attributed to poverty, inadequate prenatal care and other things. Even so, the U.S. rate generally has improved over the decades because of medical advances and public health efforts.
The 2022 and 2023 levels were up from 5.44 per 1,000 in 2021 — the first statistically significant jump in the rate in about two decades. Experts attributed those years to a rebound in RSV and flu infections after two years of pandemic precautions.
In 2023, U.S. health officials began recommending two new measures to prevent the toll on infants — one was a lab-made antibody shot for infants that helps the immune system fight off the virus, and the other was giving an RSV vaccine to women between 32 weeks and 36 weeks of pregnancy.
That effort is probably one explanation for the improvement, said Dr. Amanda Williams, interim chief medical officer for the March of Dimes.
In a separate CDC report released Thursday, researchers noted infant hospitalizations in the 2024-25 respiratory virus season were more than 40% lower than past averages.
But more work needs to be done to tease out other reasons, Williams added, noting that much of the improvement in 2024 was in infants who were at least one month old when they died. That could be explained not only by fewer deaths from RSV but also from other causes, like accidents, homicides or SIDS.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
CDC backtracks on layoffs, rehires more than 400 people
The Centers for Disease Control and Prevention is reinstating more than 400 people who had received layoff notices, according to an email from CDC leadership to employees seen by POLITICO. The rehiring, announced internally today, marks the largest number of employees that the agency has asked back to date. Around half of those employees are in the National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention, and around a third are in the National Center for Environmental Health. Other divisions seeing reinstatements include the National Center for Health Statistics, Center for Forecasting and Outbreak Analytics, Office of Human Resources, Global Health Center, Office of Acquisition Services and Office of Communications. HHS spokesperson Andrew Nixon did not immediately respond to a request for comment. He told Fox News, which first reported the news: 'The Trump Administration is committed to protecting essential services — whether it's supporting coal miners and firefighters through [the National Institute for Occupational Safety and Health], safeguarding public health through lead prevention, or researching and tracking the most prevalent communicable diseases.' — Key context: In April, roughly 2,400 CDC employees received termination notices amid a massive reorganization of the Department of Health and Human Services. But the agency has periodically rehired staff over the past few months.
The Hill
30 minutes ago
- The Hill
What to know about the new ‘Nimbus' COVID variant
The World Health Organization is keeping an eye on a new COVID-19 variant called NB.1.8.1, or 'Nimbus,' that has spread across Europe, the Americas and the Western Pacific. Nimbus is a descendant of the Omicron variant of the virus and was first identified in late January. Its spike mutations appear to make it more transmissible than other COVID variants, according to the WHO. Spike mutations refer to changes in spike proteins, which sit on the surface of the virus and help it enter healthy cells. While it is spreading in the U.S. and Canada, along with 20 other countries, it does not appear to be driving an increase in sickness or hospitalization. In April, NB.1.8.1 sequences made up 10.7 percent of all submitted sequences from confirmed COVID infections, up from 2.5 percent a month earlier, according to a risk evaluation released by the WHO. The WHO last month deemed NB.1.8.1 a variant 'under monitoring.' Here's what to know about the variant. Most cases of COVID-19 in the U.S. still stem from the LP.8.1 strain, another Omicron descendant. But it looks like NB.1.8.1 might soon replace it as the more common strain, according to data from the Centers for Disease Control and Prevention (CDC). The CDC estimates that 37 percent of COVID-19 cases in the U.S. stem from the NB.1.8.1 variant while 38 percent are a result from an infection of the LP.8.1 strain of the disease. At the end of May, the agency estimated that the NB.1.8.1 variant caused about 15 percent of all COVID cases. But the agency notes on its website that due to low numbers of virus sequences being reported, precision in the most recent reporting period is low. The NB.1.8.1 variant has been found in at least 13 states, according to Today, which cited data from the Global Initiative on Sharing All Influenza Data (GISAID) database. Those states are: California, New York, New Jersey, Maryland, Arizona, Illinois, Hawaii, Massachusetts, Ohio, Rhode Island, Vermont, Virginia and Washington. The available data on 'Nimbus' suggests that it poses a low global threat and that existing COVID-19 vaccines provide adequate protection against severe illness and hospitalization, according to the WHO. 'Currently approved COVID-19 vaccines are expected to remain effective to this variant against symptomatic and severe disease,' reads the WHO's risk evaluation. 'Despite a concurrent increase in cases and hospitalizations in some countries where NB.1.8.1 is widespread, current data do not indicate that this variant leads to more severe illness than other variants in circulation.' Lionel Gesh, an international consultant at the WHO, told The Hill that many new cases in Canada are likely linked to the NB.1.8.1 variant, but that there has not been any major changes in the country in terms of cases, hospitalizations, ICU admissions or deaths linked to COVID-19. Symptoms of NB.1.8.1 seem to be similar to those associated with other Omicron variants, according to Gresh. Some common COVID-19 symptoms include cough, fever, fatigue, muscle aches, congestion, headache, nausea, vomiting, and a new loss of smell or taste, according to the CDC. 'We should be as concerned about [NB.1.8.1] as we are concerned for COVID in general,' Gesh said. 'Not more, not less.' Some recent COVID-19 patients have reported experiencing something called 'razor blade throat,' according to Salon. But it is unclear if that symptom is connected to one of the COVID variants or another respiratory illness circulating, Ryan Gregory, an evolutionary and genome biologist at the University of Guelph in Canada, told the outlet.
USA Today
32 minutes ago
- USA Today
Unpacking RFK's lengthy social media post after firing vaccine committee members
Unpacking RFK's lengthy social media post after firing vaccine committee members Show Caption Hide Caption RFK Jr. expels entire CDC vaccine advisory committee Health Secretary Robert Kennedy Jr. removed a 17-member panel at the Centers for Disease Control and Prevention that issues recommendations on vaccines. unbranded - Newsworthy A day after abruptly firing the entire committee that advises the federal government on vaccine safety, Health and Human Services Secretary Robert F. Kennedy Jr. said he would reconstitute it with 'highly credentialed physicians and scientists' amid backlash from his detractors about the terminations. In a long post on X on June 10, Kennedy criticized the process by which the Advisory Committee for Immunization Practices recommends new vaccines, implying that "adequate safety trials" were not being conducted before recommending new vaccines to children, a notion that was strongly disputed by vaccine experts. Kennedy, who has a long record of promoting anti-vaccine views, also said the new Advisory Committee for Immunization Practices will have no 'ideological anti-vaxxers' but that the committee will apply 'evidence-based decision-making with objectivity and common sense.' 'The most outrageous example of ACIP's malevolent malpractice has been its stubborn unwillingness to demand adequate safety trials before recommending new vaccines for our children,' he wrote. Kennedy said a compliant American child receives more shots now from conception to 18 years of age compared to 1986, none of which required placebo-controlled trials. That was the year when the Vaccine Injury Compensation Program was set up, protecting vaccine makers from liability and establishing a federal program to compensate individuals injured by certain vaccines. 'This means that no one can scientifically ascertain whether these products are averting more problems than they are causing,' he wrote. A placebo-controlled study is a type of clinical trial where one group of participants receives an active treatment, while another group receives an inactive substance, helping researchers to determine whether the active treatment is truly effective. But conducting placebo-controlled studies on vaccines that are improvements on existing vaccines presents ethical and practical challenges, say vaccine experts. 'If a vaccine for a serious disease (e.g., measles, polio) already exists and is proven effective, giving participants a placebo instead of the vaccine could expose them to preventable harm or death,' wrote Dr. Jerome Adams, the former U.S. Surgeon General under President Trump's first term, in a June 9 post on X. How do vaccines work? Medical experts explain. New vaccines always undergo a placebo-controlled study, said Dr. Paul Offit, director of the Vaccine Education Center at Children's Hospital of Philadelphia and a member of the Food and Drug Administration Vaccines and Related Biological Products Advisory Committee. But Kennedy's definition of placebo is different from FDA's, said Offit. Kennedy has sought to narrowly define placebos as salt water, said Offit, while the FDA defines it as an 'inactive substance.' 'A placebo may contain sodium sulfate or potassium sulfate or may contain sucrose, or it may contain an emulsifier – those are all generally regarded as safe,' said Offit. 'He doesn't regard them as safe.' HHS did not respond to USA TODAY seeking a comment on how Kennedy's definition differs from that of the FDA. Offit said Kennedy is a lawyer who has spent years suing pharmaceutical companies, and 'his job is to scare people about vaccines ultimately, so he can bring them back to court and sue companies,' he said. Meanwhile, in his announcement of the removal of the 17 members of the ACIP committee Kennedy said the purpose was to insulate the committee from 'conflicts of interest.'
